SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Regeneron Pharmaceuticals, Inc.'s ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy